Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of Lutathera with carboplatin, etoposide, and atezolizumab in newly diagnosed extensive-stage small cell lung cancer
MOH_2024-09-18_013651Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Sep 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium Lu 177 dotatate in small cell lung cancer (SCLC) (3 arms), sponsored by Novartis. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2024-09-18_013651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-18_013651.